Improving Efficiencies in Oncology Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Roy Herbst and David Rimm discuss ways in which the time required to complete biomarker testing can be reduced, from obtaining and processing tissues, performing the testing, evaluating results, and reporting results to the cancer care team.
Dr. Stainthorpe explains that when it comes to bringing personalized medicines to fruition, the challenge is the same worldwide. It is an effort that requires better understanding of disease pathways and markers as well as improved diagnostics.
Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.